Virtual Reality Program to Teach Heart Health to Women Receiving Anthracyclines or Trastuzumab for Breast Cancer

What this Trial Is About

Researchers are evaluating a virtual reality VR program called Survivors Virtual Reality Survivorship Experience SurviVRSE designed to help breast cancer survivors who have received anthracyclines or trastuzumab learn about heart health. The study aims to test how usable, feasible, and acceptable this VR intervention is for educating survivors about cancer therapy-related cardiac dysfunction CTRCD and promoting heart-healthy behaviors. Participants will receive access to the VR cardiovascular health education and gaming program during one infusion treatment session. They will complete all education modules and games focused on understanding potentially cardiotoxic treatments, identifying cardiovascular dysfunction related to cancer therapy, and adopting heart-protective behaviors during survivorship. The intervention is delivered as a behavioral approach to support survivors knowledge and lifestyle. Participants will complete a baseline survey before the VR session, a survey within two days after the intervention, and a final survey one month later. Researchers will assess knowledge of CTRCD, usability, acceptability, user satisfaction, physical activity, sleep quality, tobacco use, and intent to change behavior during these timepoints. The study will monitor changes over four weeks to evaluate learning and behavior shifts following the VR experience.

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab